Disc Medicine FY2024 EPS Forecast Raised by HC Wainwright

Disc Medicine, Inc. (NASDAQ:IRON) – Stock analysts at HC Wainwright upped their FY2024 EPS estimates for Disc Medicine in a research note issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($3.88) per share for the year, up from their prior estimate of ($3.91). HC Wainwright currently has a “Buy” rating and a $118.00 price objective on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share. HC Wainwright also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.88) EPS, Q1 2025 earnings at ($1.02) EPS, Q2 2025 earnings at ($1.17) EPS, Q3 2025 earnings at ($1.33) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($4.87) EPS, FY2026 earnings at ($3.94) EPS, FY2027 earnings at ($3.38) EPS and FY2028 earnings at ($1.50) EPS.

A number of other equities analysts also recently weighed in on IRON. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. Wedbush reaffirmed an “outperform” rating and set a $83.00 target price (up from $75.00) on shares of Disc Medicine in a research report on Tuesday. Wells Fargo & Company started coverage on Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, October 15th. Finally, Morgan Stanley raised Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price for the company in a report on Tuesday, November 5th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $85.80.

Disc Medicine Price Performance

Shares of IRON stock opened at $60.67 on Friday. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.60. The stock has a 50-day moving average of $51.02 and a 200-day moving average of $44.75.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.15.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IRON. Frazier Life Sciences Management L.P. increased its stake in Disc Medicine by 123.5% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after acquiring an additional 969,834 shares during the last quarter. Logos Global Management LP bought a new stake in Disc Medicine in the second quarter worth $41,690,000. Point72 Asset Management L.P. purchased a new stake in Disc Medicine during the 2nd quarter valued at about $34,318,000. Deerfield Management Company L.P. Series C boosted its stake in shares of Disc Medicine by 53.8% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after purchasing an additional 357,730 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Disc Medicine by 59.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after acquiring an additional 353,382 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Insider Activity at Disc Medicine

In other news, Director William Richard White sold 7,136 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total transaction of $418,240.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 7,538 shares of company stock worth $437,875. 4.24% of the stock is owned by corporate insiders.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.